Autor/es: Alejandro M. Aragona, MD,*† Nicasio Cuneo, MD,* Alejandro H. Soderini, MD,* Elsa Alcoba, MD,‡ Adriana Greco, MD,§ Carlos Reyes, MD,|| and Silvia Lekmann, MD||
*Department of Gynecologic Oncology, Oncologic Hospital of Buenos Aires Marie Curie; †University of Buenos Aires (UBA); ‡Division of Anatomic Pathology, Department of Gynecologic Oncology, Oncologic Hospital of Buenos Aires Marie Curie; §Division of Gynecology, Parmenio Piñero Hospital; and ||Unit of Gynecologic Oncology, Division of Gynecology, Parmenio Piñero Hospital, Buenos Aires, Argentina.
Resumen: The use of NCH in selected groups may increase surgical feasibility in initially inoperable patients, thus favoring organ preservation and less extensive resections. Adverse reactions were acceptable, and vulvoperineal deleterious effects that may occur after radiotherapy were consequently avoided.
